Development of a stability-indicating UPLC method for determining olanzapine and its associated degradation products present in active pharmaceutical ingredients and pharmaceutical dosage forms

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 4, 2011, Pages 667-673

  Krishnaiah, Ch ^a,b   Vishnu Murthy, M ^a   Kumar, Ramesh ^a   Mukkanti, K ^b  

^a DR REDDY'S LABORATORIES LTD   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Forced degradation; Olanzapine; Stability indicating; UPLC; Validation

Indexed keywords

OLANZAPINE;

ACCURACY; ANALYTIC METHOD; ARTICLE; CHROMATOGRAPHY; DRUG DETERMINATION; DRUG DOSAGE FORM; HYDROLYSIS; OXIDATION; PHOTODIODE ARRAY DETECTOR METHOD; PHOTOLYSIS; PRIORITY JOURNAL; REPRODUCIBILITY; TEMPERATURE; TEMPERATURE STRESS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDITY;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; DRUG STABILITY; HOT TEMPERATURE; HYDROGEN-ION CONCENTRATION; LIMIT OF DETECTION; OXIDATION-REDUCTION; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS; ULTRAVIOLET RAYS;

EID: 78650253901     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.10.013     Document Type: Article

References (19)

1. Rao R.N., Raju A.N., Narsimha R., Babu G.R. Isolation and characterization of process related impurities of olanzapine using HPLC and ESI-MS/MS. J. Sep. Sci. 2008, 31:107-118.
2. Hiriyanna S.G., Basavaiah K., Goud P.S.K., Dhayanithi V., Raju K., Pati H.N. Identification and characterization of olanzapine degradation products under oxidative stress conditions. Acta Chromatogr. 2008, 20:81-93.
3. Steven W.B., Heiko B., Charles A.B., Gary G.C., Benjamin D., Douglas E.D., Patrick J.J., Craig Kemp A.J., Steven R.M., Karen McCune A., Jeffrey Speakman L. Isolation and synthesis of two oxidative degradation products of olanzapine (LY170053) in solid oral formulations. J. Pharm. Sci. 2007, 97:883-892.
4. Poornachander T., Kumar R., Chandrasekhar B., Ramesh Ch., Pratap P.R., Anjaneyulu Y., Satyanarayana B. Synthesis and characterization of impurities of an anti-psychotic drug substance. Olanzapine Synth. Commun. 2008, 24:195-201.
5. Rajendraprasad N., Basavaiah K., Tharpa K., Vinay K.B. Quantitative determination of olanzapine in tablets with visible spectrophotometry using cerium(IV) sulphate and based on redox and complexation reactions. Eurasian J. Anal. Chem. 2009, 4:191-203.
6. Ramakrishna V.S.N., Vishwottam K.N., Manoj S., Koteshwara M., Santosh M., Ravikumar B., Anjaneyulu Y. Development and validation of a sensitive liquid chromatography, electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma. J. Pharm. Biomed. Anal. 2006, 41:935-942.
7. Leon J.D., Peter L.H., Linda M.F., Kenneth F.I. Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection. J. Chromatogr. B 2002, 773:191-197.
8. Zhou Z., Li X., Li K., Xie Z., Cheng Z., Peng W., Wang F., Zhu R., Li H. Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. B 2004, 802:257-262.
9. Stephen C.K., Edward L.M., Steven P.S., Andre C.J., Jason T.J., Carlos O.G. Determination of olanzapine in human breast milk by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. Sci. 1999, 726:203-209.
10. Pathak A., Rajput S.J. Development of a stability-indicating HPLC method for simultaneous determination of olanzapine and fluoxetine in combined dosage forms. J. Chromatogr. Sci. 2009, 47:605-611.
11. Raggi M.A., Casamenti G., Mandrioli R., Izzo G., Kenndler E. Quantitation of olanzapine in tablets by HPLC, CZE, derivative spectrometry and linear voltammetry. J. Pharm. Biomed. Anal. 2000, 23:973-981.
12. Bi{dotless}ryol I., Erk N. Voltammetric spectrophotometric, and high performance liquid chromatographic analysis of olanzapine. Anal. Lett. 2003, 36:2497-2513.
13. Nielsen M.K.K., Johansen S.S. Determination of olanzapine in whole blood using simple protein precipitation and liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 2009, 33:212-217.
14. Bao J.Q., Potts B.D. Quantitative determination of olanzapine in rat brain tissue by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B 2001, 752:61-67.
15. Sabbioni C., Saracino M.A., Mandrioli R., Albers L., Oncompagni G., Raggi M.A. Rapid analysis of olanzapine and desmethylolanzapine in human plasma using high-performance liquid chromatography with coulometric detection. Anal. Chim. Acta 2004, 516:111-117.
16. Firdous S., Aman T., Nisa A. Determination of olanzapine by UV spectrophotometry and non-aqueous titration. J. Chem. Soc. Pak. 2005, 27:163-167.
17. Shah C.R., Suhagia B.N., Shah N.J., Patel D.R., Patel N.M. Stability-indicating simultaneous HPTLC method for olanzapine and fluoxetine in combined tablet dosage form. Indian J. Pharm. Sci. 2008, 70:251-255.
18. ICH Q1A (R2), Stability Testing of New Drug Substances and Products, 2003.
19. ICH Q2 (R1), Validation of Analytical Procedures: Text and Methodology, 2005.